Home Companies Catalysts Deep Dives

Follicular lymphoma

FL · Oncology · 3 drugs · 4 indications

Indolent B-cell non-Hodgkin lymphoma.
Competitive Landscape (3 drugs)
DrugCompanyMechanismModalityRouteStage
OdronextamabREGNCD20xCD3 bispecificBispecific antibodyIVPHASE3
LunsumioROG.SWCD20xCD3 T-cell engagerBispecificSC/IVAPPROVED
EpkinlyABBV, GMABCD20xCD3 bispecificBispecificSCAPPROVED
Indications (4)
R/R FL
Lunsumio APPROVEDEpkinly APPROVED
R/R follicular lymphoma
Epkinly APPROVED
Relapsed/refractory follicular lymphoma
Relapsed/refractory follicular lymphoma (3L+)
Odronextamab PHASE3
Upcoming Catalysts
Lunsumio + Polivy - DLBCL - FDA ApprovalREGULATORY
ROG.SWH1 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-4)CLINICAL
ABBVH1 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-2)CLINICAL
ABBVH2 2026
Odronextamab - R/R FL - Ph3 ToplineCLINICAL
REGN2026-2027
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-2)CLINICAL
GMABH2 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-4)CLINICAL
GMABH2 2026
Data from Supabase · Updated 2026-03-24